Immune-checkpoint inhibitors have revolutionized the treatment of patients with non-small-cell lung cancer (NSCLC). Recently, indications for immune-checkpoint inhibitors have expanded from advanced-stage NSCLC to adjuvant, and now neoadjuvant, therapy for resectable NSCLC, with three cycles of preoperative chemoimmunotherapy achieving superior pathological complete response rates and event-free survival compared with chemotherapy alone in the phase III CheckMate 816 trial.

中文翻译：

---

新辅助化学免疫疗法在可切除 NSCLC 中的作用

免疫检查点抑制剂彻底改变了非小细胞肺癌 (NSCLC) 患者的治疗。最近，免疫检查点抑制剂的适应症已从晚期 NSCLC 扩大到可切除 NSCLC 的辅助治疗和现在的新辅助治疗，在第三阶段 CheckMate 816 试验。